Facility Overview

Medicago operates a 14,000-square-foot production facility located in the “Parc Technologique du Québec Métropolitain” in Québec City, Québec. This facility includes a 10,000 sq.ft Biosafety level 2 greenhouse and a 3,000 sq.ft extraction and primary purification unit and is cGMP compliant. Medicago also rents approximately 13,000 sq.ft in Québec City of which 2,500 sq.ft are dedicated to final steps of purification under cGMP conditions and the remaining is for storage and office space. Medicago expects to produce the preclinical and clinical lots required for the development of its influenza vaccines from its existing facilities.

Medicago U.S.A., a wholly owned subsidiary of Medicago Inc., has commenced the construction of its cGMP facility in Research Triangle Park (RTP), North Carolina. This vaccine facility will include a fully automated greenhouse and a state of the art extraction and purification unit. The 97,000-square-foot cGMP facility will have the capacity to produce more than 40 million doses of seasonal influenza vaccine or 120 million doses of pandemic influenza vaccine a year. The facility is scheduled to be complete in 2011.